Inhibition of bromodomain and extra‐terminal proteins increases sensitivity to venetoclax in chronic lymphocytic leukaemia

The development of drugs able to target BTK, PI3k‐delta and BCL2 has dramatically improved chronic lymphocytic leukaemia (CLL) therapies. However, drug resistance to these therapies has already been reported due to non‐recurrent changes in oncogenic pathways and genes expression signatures. In this...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Cell Mol Med
Päätekijät: Carrà, Giovanna, Nicoli, Paolo, Lingua, Marcello Francesco, Maffeo, Beatrice, Cartellà, Antonio, Circosta, Paola, Brancaccio, Mara, Parvis, Guido, Gaidano, Valentina, Guerrasio, Angelo, Saglio, Giuseppe, Taulli, Riccardo, Morotti, Alessandro
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2019
Aiheet:
Original Articles
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6991693/
https://ncbi.nlm.nih.gov/pubmed/31821686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/jcmm.14857
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia